(Q38861792)

7 September 2017

title

PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy (English)

1 reference

7 September 2017

1 reference

Georg Nuebling

1

1 reference

7 September 2017

Mira Hensler

2

1 reference

7 September 2017

Sabine Paul

3

1 reference

7 September 2017

Andreas Zwergal

4

1 reference

7 September 2017

Alexander Crispin

5

1 reference

7 September 2017

Stefan Lorenzl

6

1 reference

7 September 2017

publication date

26 May 2016

1 reference

7 September 2017

1 reference

7 September 2017

volume

263

1 reference

7 September 2017

issue

8

1 reference

7 September 2017

page(s)

1565-1574

1 reference

Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

New insights into progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Progressive supranuclear palsy: clinical features, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

A clinical rating scale for progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

FAB-D: German version of the Frontal Assessment Battery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Dementia and depression determine care dependency in Parkinson's disease: analysis of 1,449 outpatients receiving nursing care in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Postural imbalance with head extension: improvement by training as a model for ataxia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Rate of decline in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Depression rating scales in Parkinson's disease: critique and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Postural imbalance and falls in PSP correlate with functional pathology of the thalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Functional disturbance of the locomotor network in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8169-1

Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27230855

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Retrospective study of drug response in 87 patients with progressive supranuclear palsy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27230855

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-016-8169-1

1 reference

Dimensions Publication ID

7 September 2017

1048455242

0 references

1 reference